U.S. abortion rate holds steady as telehealth expands

The U.S. abortion rate was broadly unchanged in 2025 even as multiple states maintained bans or tighter limits, with more patients relying on remote care and fewer traveling long distances for services.

The Guttmacher Institute said the overall number of abortions edged up slightly to 1.126 million in 2025 from 1.124 million in 2024, pointing to a shift in how care is accessed rather than a sharp change in total demand.

What changed in 2025

Interstate travel for abortion care declined again. About 142,000 people crossed state lines for care in 2025, down from 154,000 in 2024 and 170,000 in 2023, the report found.

The drop was concentrated among residents of states with total bans. Guttmacher reported that 12,000 fewer people from those states traveled in 2025 than in the prior year, even though 62,000 still did so—more than twice the level seen before the U.S. Supreme Court’s Dobbs decision.

Telehealth and mail delivery take a larger role

Guttmacher attributed the steadier national totals in part to a growing reliance on telehealth consultations and mailed medication. The report described a notable movement away from in-person travel toward remote pathways for obtaining abortion pills.

A key enabler has been “shield law” frameworks in some states, including New York and Massachusetts. These policies are designed to protect clinicians who provide remote visits and prescribe medication to patients located in states with bans, including places such as Texas and Alabama.

Why it matters now

The data suggest that restrictions in one jurisdiction can be partially offset by cross-border services and remote prescribing, changing the operational landscape for providers, pharmacies, telehealth platforms, and state regulators. For patients, the report indicates that medication-based options can reduce the need for travel and may lower out-of-pocket costs compared with arranging transportation and time off work.

At the same time, the report’s findings highlight an uneven access picture: fewer people traveling does not, by itself, reveal how many were unable to obtain care, and the source material does not quantify unmet demand or delays.

Regulatory outlook and uncertainty

Federal policy could still reshape access. The U.S. Food and Drug Administration is reviewing rules tied to dispensing mifepristone, one of the medications used in abortion care, and potential adjustments are anticipated after the midterm elections.

Because the FDA review is ongoing, the timing and substance of any changes remain unclear. That uncertainty matters for telehealth providers and mail-order fulfillment models that have become more central as patients adapt to state-level restrictions.